Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

well as a license from Alnylam. The Company has licensed RTP801i-14 to Pfizer on an exclusive worldwide basis. Quark has, in addition, a product candidate portfolio of RNAi therapeutics based on novel targets and therapeutic concepts discovered using BiFAR(TM) and designed for the treatment of oxidative stress associated diseases of the inner ear, lungs and additional organs of the body.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com

Quark Pharmaceuticals, Inc.

Gavin Samuels

(510) 449 6737

GSamuels@quarkpharma.com

The Ruth Group

Stephanie Carrington / Elizabeth Scott (investors)

(646) 536-7017 / 7014

scarrington@theruthgroup.com

escott@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...   Gulf Coast Tattoo Removal is the first and ... Duality laser in Southern Mississippi . Gulf Coast ... and take back control of their skin. The clinic is located ... to Biloxi , Gulfport , ... being as prevalent as it is, I was surprised by the ...
(Date:9/2/2015)... 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Financial Officer of Neurocrine Biosciences, will be presenting at ... York City . The live presentation ... (8:25am PT).  The presentation will be webcast and may ... .   Listeners are encouraged to visit ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015  ArmaGen, ... developing revolutionary therapies to treat severe neurological disorders, ... dosed in its multi-center Phase 1/2a clinical trial ... I (MPS I). AGT-181 is ... treatment of MPS I. The most severe form ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
(Date:9/3/2015)... , ... September 03, 2015 , ... Hunters Creek ... Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited ... for friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... concierges; simplifying responsibilities which can impact the delicate life balance between work and ... might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency Care ...
(Date:9/3/2015)... Angeles, CA (PRWEB) , ... September 03, 2015 , ... ... iTunes , Google Play , and Amazon and will be ... the lead from “My Darling is a Foreigner,” Itsuka, an actress and singer/songwriter, and ...
(Date:9/3/2015)... ... 03, 2015 , ... The new In-Office whitening kit from ... The Clinicians Report is a leading information source to the dental industry. Product ... Whiter Image's In-Office whitening kits were favorably validated for use in the dental ...
(Date:9/3/2015)... ... 2015 , ... About 220,800 new cases of prostate cancer are reported each year, along with ... prostate cancer during their lifetime. While only one man in 10,000 will typically get prostate ... 65, according to the American Cancer Society. , Prostate cancer is ...
Breaking Medicine News(10 mins):Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... CHICAGO Results of clinical research on new presbyopia treatments ... the United Stateswere reported in today,s Scientific Program of ... Ophthalmology (AAO) and Middle East-Africa Council of Ophthalmology ... comprehensive ophthalmic education conference and is in session October ...
... the world of business-performance experts and baseball talent scouts, ... to find a way to measure the productivity of ... findings the most recent issue of Science Translational ... contributions of individual scientists, judging the effectiveness of team ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... average, untrained person can still save a life by focusing ... Heart Association. The simplified form of cardiopulmonary resuscitation, or ... -- and the oxygen in the blood -- flowing to ...
... HealthDay Reporter , MONDAY, Oct. 18 (HealthDay News) -- ... non-heart surgery had a higher risk of death in the ... found. And, patients who hadn,t been diagnosed with diabetes ... higher risk of death in the year after a surgical ...
... cancers can be divided into different subtypes based on ... protein to which the female hormone estrogen binds; that ... tumors have a worse outlook than those with ER-positive ... characterized as basal-like are the most aggressive and difficult ...
... American descent Latinas - from using cancer screening ... Dr. Linda Gallo from San Diego State University in ... are pessimistic about preventive health practices and disease outcomes ... breast and colorectal cancer. The research is published online ...
Cached Medicine News:Health News:New vision correction options for baby boomers 2Health News:New vision correction options for baby boomers 3Health News:New vision correction options for baby boomers 4Health News:Is team science productive? 2Health News:Is team science productive? 3Health News:New CPR Guidelines Emphasize Compressions First 2Health News:New CPR Guidelines Emphasize Compressions First 3Health News:Even Well-Controlled Diabetes May Present Post-Surgery Risk 2Health News:Even Well-Controlled Diabetes May Present Post-Surgery Risk 3Health News:Latinas: 'Cancer was just meant to be' 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
Inquire...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Medicine Products: